The same check also demonstrated the capability to distinguish Alzheimer’s from Parkinson’s disease, a related neurodegenerative disorder closely. The research team’s findings appear online in PLoS ONE. A lot more than 100 years after it was first described, Alzheimer’s affects nearly 36 million people worldwide, yet there remains only 1 definitive way to diagnose the condition – the direct examination of brain tissue following the patient’s death There’s a dire need for an accurate, relatively noninvasive and inexpensive diagnostic check for Alzheimer’s, said Robert Nagele, PhD, founder of Durin Systems, Inc., and a professor at the UMDNJ-College of Osteopathic Medicine. A test that can not only diagnose the condition in individuals showing telltale symptoms, but probably also detect the disease years before these symptoms show up would make early therapeutic intervention feasible.The session titled, ‘SETTING UP Biotechs in the New Normal Globe,’ will become moderated by Lynn Yoffee, Controlling Editor of BioWorld Today, and occurs from 10:00 AM to 11:30 AM in room 149 Abdominal of the Walter E. Washington Convention Middle. Related StoriesMD Anderson research reveals why chemotherapy medications not effective for many pancreatic cancer patientsOvarian tumor patients with a brief history of oral contraceptive make use of possess better outcomesSausages With Antioxidants From Berries TO AVOID CancerAcetylon can be applying its scientific knowledge to the development of little molecule HDAC inhibitors that build upon the proven therapeutic potential of HDAC inhibition but are differentiated by improved enzyme target selectivity.